Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...

The money will go to Moderna, the Massachusetts-based pharmaceutical company that previously developed a COVID-19 vaccine.

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Jan 17 (Reuters) - The U.S. government has awarded Moderna (MRNA.O), opens new tab $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.